UK Markets close in 4 hrs 3 mins

Novo Nordisk A/S (NOVO-B.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
1,026.80+7.60 (+0.75%)
As of 01:27PM CET. Market open.

Novo Nordisk A/S

Novo AllE 1
Bagsvaerd 2880
45 44 44 88 88

Full-time employees54,393

Key executives

NameTitlePayExercisedYear born
Mr. Lars Fruergaard JorgensenPres, CEO & Member of Management Board32.3MN/A1966
Mr. Karsten Munk KnudsenExec. VP, CFO & Member of the Management Board12.8MN/A1971
Mr. Henrik Ehlers WulffExec. VP, Head of Product Supply, Quality & IT and Member of the Management Board12.9MN/A1970
Ms. Camilla SylvestExec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board12.6MN/A1972
Ms. Monique CarterExec. VP, Head of People & Organisation and Member of Management Board9.7MN/A1973
Mr. Maziar Mike DoustdarExec. VP, Head of International Operations & Member of the Management BoardN/AN/A1970
Mr. Douglas J. LangaExec. VP, Head of North America Operations & Member of Management BoardN/AN/A1966
Mr. Ludovic HelfgottExec. VP, Head of Rare Disease & Member of Management BoardN/AN/A1974
Dr. Martin Holst LangeExec. VP, Head of Devel. & Member of the Management BoardN/AN/A1970
Dr. Marcus Schindler Ph.D.EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management BoardN/AN/A1966
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in DKK.


Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Corporate governance

Novo Nordisk A/S’s ISS governance QualityScore as of 1 February 2023 is 1. The pillar scores are Audit: 2; Board: 2; Shareholder rights: 10; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.